Pharmaceutical

Keros Therapeutics considers sale amid investor pressure

The biotech has launched a strategic review to consider options, including a possible sale, following shareholder pressure.

Apr 12, 2025 - 06:00
Keros Therapeutics considers sale amid investor pressure
The biotech has launched a strategic review to consider options, including a possible sale, following shareholder pressure.
Read the original article

Tags:

Previous Article

FDA approves Biocon Biologics’ bevacizumab biosimilar for cancer

Next Article

Cingulate secures $3m to advance once-daily anxiety treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: How the U.S. health care system is like a Jackson Pollock painting

Opinion: How the U.S. health care system is like a Jack...

Apr 5, 2023

US FDA accepts Accord BioPharma’s BLA for HLX02 to treat cancer

US FDA accepts Accord BioPharma’s BLA for HLX02 to trea...

Apr 6, 2023

FDA rejects Alvotech’s BLA for Stelara biosimilar

FDA rejects Alvotech’s BLA for Stelara biosimilar

Oct 13, 2023